B
Bull
Bull · 25%EDSA
$3.51
Precio del escenario
$4.780
+0.045 (+0.95%)Al cierre
Loading chart…
- High
- 5.010
- Open
- 4.780
- VWAP
- 4.80
- Vol
- 24.07K
- Mkt Cap
- 13.76M
- Low
- 4.610
- Amount
- 115.53K
- EV/EBITDA, TTM
- 0.00
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
AI analysis of Edesa Biotech Inc (EDSA)
buyEdesa Biotech Inc (EDSA) is a good buy right now due to its recent price drop to $4.62, which is significantly below the analyst price target of $21, indicating a potential upside of over 354%. Additionally, the stock has shown a strong year-to-date change of +208%, suggesting robust performance despite recent challenges. However, the company is facing a risk with a widening net loss reported at $5.4 million for the last quarter, which is a concern for long-term profitability.
Métricas de valoración
The current forward P/E ratio for Edesa Biotech Inc (EDSA) is 0.18, compared to its 5-year average forward P/E of -2.00.
Alphio AI Price Scenarios for EDSA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.508-20NASDAQ.COMEdesa Biotech Prices Public Offering at $5.50 per Share
8.508-20NASDAQ.COMEdesa Biotech Launches Underwritten Public Offering
8.508-20NewsfilterEdesa Biotech Prices Public Offering to Raise $25 Million
8.506-24NASDAQ.COMBoundless Bio Merges with Serapha in All-Stock Deal
- 8.506-12NASDAQ.COM
Edesa Biotech Announces PIPE Placement to Raise $3.5 Million
EDSA FAQ — answered by Alphio AI
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Edesa Biotech Inc (EDSA) is a good buy right now due to its recent price drop to $4.62, which is significantly below the analyst price target of $21, indicating a potential upside of over 354%. Additionally, the stock has shown a strong year-to-date change of +208%, suggesting robust performance despite recent challenges. However, the company is facing a risk with a widening net loss reported at $5.4 million for the last quarter, which is a concern for long-term profitability.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.